GC021109 / GliaCure - LARVOL DELTA

GliaCure completes successful proof of concept Phase 1b clinical trial in Alzheimer's disease (PRNewswire) - "GliaCure...announced today that it has successfully completed a Phase 1b clinical trial of its lead product candidate, GC021109...GliaCure reported that the pooled trial results showed a statistically significant change in amyloid β in the cerebrospinal fluid of subjects dosed with drug compared to placebo, potentially demonstrating GC021109's usefulness in treating Alzheimer's disease."

P1 data • Alzheimer's Disease